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Despite insights from large-scale genomic 
studies, there has been limited success in 
reversing the declining approval rate for new 
drugs, across all types of human diseases [1]. 
Even in oncology, where a significant num-
ber of personalized medicines that target the 
genetic drivers of cancers have been approved, 
the number of new drugs is dwarfed by the 
volume of driver genes identified [2].
Attrition rates in the clinic remain unaccept-
ably high, with only 10% of drugs transition-
ing from Phase I to approval [3]. Some studies 
show that oncology has the lowest success rate 
at around 7% [3] and the highest rate of late-
stage failures in the clinic [4]. The major cause 
of failure is lack of efficacy [4] which can often 
be attributed to inadequate patient stratifica-
tion for the pivotal trial or, significantly earlier, 
poor preclinical target validation. Apocryphal 
tales and increasingly more detailed reports 
of a lack of reproducibility of biological data 
fill the scientific airways [5,6]. With the cost of 
developing a single drug estimated in excess 
of US$2.5 billion, it is not surprising that the 
Pharma industry has focused heavily on well-
established targets and pathways – commonly 
sacrificing innovation for the sake of risk miti-
gation [7]. Indeed, our analysis shows that most 
approved cancer drugs target only a small part 
of cancer’s intricate cellular networks [2,8].
Yet, our need for mechanistically inno-
vative cancer drugs has never been greater. 
The genetic and epigenetic heterogeneity 
of cancer means that oncology’s previous 
one-size-fits-all approach to treatment is 
no longer valid. Moreover, we are fighting 
a constant battle against adaptive biochemi-
cal and transcriptional responses, clonal 
evolution and the incessant emergence of 
drug resistance to previously successful tar-
geted therapies – making new approaches 
e ssential [9–13].
Therefore as a community, we face clear 
and urgent challenges: How do we expand 
our repertoire of innovative, mechanistically 
distinct drugs against robustly validated tar-
gets for cancer? How do we overcome the 
inexorable march of drug resistance?
A key underlying solution is making the 
best possible choice of new, innovative drug 
targets. Here, we argue the case for mini-
mizing bias in target selection by exploiting 
multidisciplinary Big Data and assessing tar-
gets based on their biological, chemical and 
physical properties, as well as their role in the 
cellular protein interactome.
Objective assessment of targets
To make the best decisions one must be armed 
with as much relevant knowledge as possible. 
“Here, we argue the case for minimizing bias in target 
selection by exploiting multidisciplinary Big Data and 
assessing targets based on their biological, chemical and 
physical properties, as well as their role in the cellular 
protein interactome.”
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Rather than assess the suitability of a target for drug 
discovery using only narrow biological criteria and/or a 
simple glance at ‘druggability’, we argue that one should 
examine all known data from different disciplinary 
domains in an objective fashion for a range of potential 
targets. This is particularly important when selecting tar-
gets from a large functional screen [14] or omic [15] analy-
sis. A major challenge comes when these campaigns gen-
erate large lists of potential targets, about many of which 
very little is known. The natural tendency would be to 
select from these gene lists those that are more familiar 
to us or those that belong to one of the handful of well-
studied and validated cancer pathways. Such human bias 
negates the value of the unbiased screen or omic analysis. 
Unbiased target discovery surely needs to be comple-
mented by similarly unbiased, optimally evidence-based 
target  comparison, prioritization and selection.
To address this, we developed and made publicly 
available an approach for data-driven, unbiased priori-
tization of cancer targets. We have brought together, 
within a single knowledgebase, vast multidisciplinary 
data on genomics (including integrated linkage to 
The Cancer Genome Atlas data [16]) and the biology, 
pharmacology and chemistry of genes and proteins, 
incorporating integrated linkage to the ChEMBL 
database [17] along with relevant clinical information 
and multiple alternative views of druggability. Using 
this approach we have demonstrated the ability of our 
integrated and unbiased large-scale approach to iden-
tify otherwise ignored but biologically important and 
druggable cancer targets [2,18–19].
canSAR: Integrating Big Data for drug 
discovery
To enable such objective, data-driven, unbiased and 
multidisciplinary therapeutic target assessment and 
selection, we reasoned that the community needs a 
user-friendly resource to integrate and crystallize all 
relevant data from the diverse domains. As well as pre-
senting the data in an integrated and meaningful way, 
such a resource needs powerful data analytics to ‘learn’ 
from these diverse data so as to help scientists select 
targets and generate new hypotheses. Not only is the 
sheer scale of the Big Data involved a challenge, but so 
too are the multiple different ‘languages’ – we needed 
to integrate biological, structural, chemical and clini-
cal data, and to allow information flow between these 
different disciplinary domains.
To achieve these goals we built canSAR [20–23] as a 
Big Data, multidisciplinary knowledgebase for cancer 
drug discovery (Figure 1). It brings together and inte-
grates genomic, protein sequence and structural data, 
chemical, pharmacological, biochemical and pheno-
typic data, as well as clinical annotations and data 
from clinical trials. In all, canSAR contains 1 billion 
experimental data points. Data and annotations span 
the whole human proteome, 12,000 cancer cell lines, 
>10,000 cancer patient samples, >1.2 million biologi-
cally active small molecules and >200,000 clinical tri-
als. canSAR has been utilized by >180,000 users from 
>180 countries (Google Analytics) and is accessed daily 
by around 400 researchers from major cancer research 
centers, universities and the pharmaceutical industry.
Most valuably, canSAR incorporates sophisticated 
data analytics and machine learning to facilitate the 
objective and rapid prioritization of targets for fur-
ther validation. In addition to individual or systematic 
target selection, canSAR is particularly powerful for 
hypothesis generation. It enables users to easily identify 
model systems and chemical tools for experiments and 
alerts them to potential cancer associations based on 
patient genomics or data from cellular, genetic or drug 
screens. Recently, we have incorporated significant 
amounts of new data into canSAR in two major areas: 
3D protein structures and cellular protein wiring [22].
3D protein structures inform target 
tractability
The 3D structure of proteins is a powerful tool that 
is invaluable to small-molecule drug discovery. It aids 
hit identification and structure-based drug design. 
Importantly for the present discussion, an assessment 
of the druggability of observed cavities observed on the 
3D structure should be incorporated into multidisci-
plinary target selection. This ideally requires a sophis-
ticated combination of the different kinds of physi-
cochemical and geometric analysis of cavities based 
on many different physicochemical and geometric 
properties – beyond simply just volume and enclosure. 
Moreover, as proteins are mobile flexible molecules, 
examining only one or two snapshots for druggability 
can be misleading, as one may fail to detect a drug-
gable cavity because it appears in only one specific pro-
tein conformation of the protein [2]. Also, apparently 
druggable cavities may be the result of experimental 
artifacts. Thus multiple structures are incorporated in 
canSAR wherever feasible. canSAR not only combines 
the different available approaches but importantly 
also utilizes machine learning to identify and assess 
the druggability of >110,000 structures comprising 
>310,000 individual protein chains. canSAR already 
evaluates >2,119,000 cavities of which >95,000 are 
predicted to be druggable. The availability of these 
data at a researcher’s fingertips allows the rapid and 
“The genetic and epigenetic heterogeneity of 
cancer means that oncology’s previous one-size-
fits-all approach to treatment is no longer valid.”
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objective assessment of large numbers of known or 
potential protein targets – especially when integrated 
with the other means of target analyses available 
through canSAR. Particularly important are the pub-
lished chemical landscape and pharmacology data for 
each target – allowing the rapid objective evaluation 
of large numbers of proteins. Moreover, because the 
methodology in canSAR assesses druggability based 
on 30 different physicochemical and geometric site 
properties, it can identify novel druggable regulatory 
cavities on proteins that would be missed by more 
 simple assessments [2,22].
The social life of cancer proteins
Like most humans, cancer proteins do not act in isola-
tion. Cancer results from complex, aberrant communi-
cation networks downstream of the initial oncogenic 
drivers and further deregulated by subsequent adap-
tion, evolution and malignant progression. Moreover, 
drug resistance commonly arises from the rewiring of 
cellular communication, both within the cancer cell 
and between the cell and its environment [24]. There-
fore it is surprising that cellular wiring and molecular 
communication are rarely used as criteria for assessing 
targets for drug discovery. To address this, we set out to 
establish whether there are communication behaviors 
that are unique to cancer drug targets when compared 
with the remainder of the proteome and targets from 
other disease areas [8].
We compiled and analyzed a high-confidence, 
curated network representing the experimentally 
defined human protein interactome [8] and integrated 
this into canSAR [22]. The resulting map contained 
90,000 interactions between 13,345 proteins repre-
senting a complex interaction network. By applying 
network biology theory and social networking analysis 
– akin to a molecular Facebook – we derived a commu-
nication map for this network. Our analysis showed 
that cancer proteins have distinctive ‘social’ behaviors 
when compared with targets from other disease areas 
and to the human proteome as a whole [8]. Identifi-
cation of these distinct behaviors has allowed us to 
develop novel predictors for target selection using cel-
lular interactions [8] which are now provided through 
the latest version of canSAR [22].
Significantly, our analysis demonstrated that the 
majority of cancer drug targets occupy especially 
highly connected local environments. Although these 
proteins are important for communication, strong 
local connectivity allows rapid rewiring should they 
become disabled. This is consistent with the pathway 
remodeling detected after the emergence of drug resis-
tance [10,24]. Moreover, it is consistent with resistance 
emerging when drugs acting on targets that are adja-
cent in a pathway are combined, such as BRAF and 
MEK inhibitors in the treatment of melanoma [25]. 
Interestingly, we find that the targets of immuno-
therapies – currently of major clinical and commercial 
interest – have different social environments and may 
therefore be less susceptible to compensatory pathway 
rewiring when compared with typical cancer drug 
 targets [22].
An important prediction we make is that targeted 
therapies may be of most benefit when combined with 
drugs that act on targets from different ‘social environ-
ments’. Our observations highlight the importance of 
considering these complex issues at the stage of target 
selection.
Comprehensive, continuous & live analysis 
of targets
In summary, the canSAR knowledgebase enables a 
smart, objective and user-friendly assessment of poten-
tial drug targets from a large pool of candidates – using 
integrative multidisciplinary Big Data to extend beyond 
the confines of well-trodden ground. The integration of 
diverse multidisciplinary information through canSAR 
enables hypothesis generation and facilitates the fur-
ther experimental exploration of novel targets. More-
over, as the only public resource of its particular kind – 
incorporating sophisticated data analytics and machine 
learning – canSAR empowers the cancer drug discov-
ery community to make objective decisions informed 
by multidisciplinary evidence. We argue that the vital 
step of selecting a drug target – from among the very 
many options available now in cancer – should only be 
taken after examining all that is known of a target’s 3D 
structure, biology, chemistry and pharmacology as well 
as clinical data. Moreover, we propose that a target’s 
communication pattern is crucial to its role in disease 
and behavior as a therapeutic target and canSAR now 
enables users to factor in such social network consider-
ations. We suggest that this might be especially impor-
tant in selecting targets to minimize potential for facile 
drug resistance which is a major challenge in treating 
cancer patients. Examining data from all these distinct 
domains together, in an unbiased manner, empowers 
the cancer drug discovery community, both public and 
private, to make more informed decisions. Most of the 
target selection tools and data in canSAR apply across 
human disease beyond oncology.
This is not automated target selection by computer, 
but rather provision of a powerful approach and tools to 
facilitate maximally informed target selection. Transla-
“…the canSAR knowledgebase enables a 
smart, objective and user-friendly assessment 
of  potential drug targets from a large pool of 
 candidates…”
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tional scientists and drug discoverers are now empow-
ered by easy access to all relevant information and inte-
grative data mining tools – adding as they wish to their 
own data, experience and skills. With support from our 
funders (see the Acknowledgements section), and incor-
porating user feedback [26,27], we will enhance the intui-
tive user interface and the content and analytical power 
of canSAR, including links to the cBioPortal for Cancer 
Genomics [28] and the Open Targets platform [29]. The 
frequent automated updates available through canSAR 
enable users to regularly and rapidly refresh their view 
of the changing knowledge about our present and future 
drug targets. In this way we can constantly maintain 
a very current and broad as well as detailed compara-
tive perspective of the rapidly changing challenges and 
opportunities in cancer drug discovery – and thus help 
improve success rates in clinical development and the 
defeat of drug resistance in cancer.
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